Amarin Corporation plc has used the year since the June 2025 Recordati deal to convert itself from a single-product U.S. cardiovascular drug company running an annual $70 million cost-savings project into a debt-free, positive-cash-flow, partner-driven franchise, and the Q2 2026 print filed on July 29, 2026 is the first clean quarter that proves the new model functions. Total net revenue compressed 42% year over year to $42.2 million, but that headline is a comparison artifact, because the prior-year quarter contained a one-time $25 million upfront payment from Recordati, and the underlying product franchise actually grew: branded VASCEPA prescriptions rose 14%, the company captured 48% of the U.S. icosapent ethyl market (up from 43% a year ago), and global in-market volume across the partner network rose 59%. The operating loss narrowed to $(12.0) million from $(16.0) million a year ago, and the company reported positive operating cash flow for the third consecutive quarter, finishing June 30, 2026 with $314.6 million in cash and short-term investments and zero debt.
The thesis driving the equity is that the cost reset is now structurally embedded in the P&L (the $70 million annual savings program is complete), while the partner network in Europe, China, and the Middle East is still in early innings of its commercial ramp, meaning the financial inflection point arrives as international royalties grow into a cost base that has already been cut. Our interpretation is that the equity is priced today for the international ramp to disappoint, with operating losses of roughly $35 million annualized on a first-half run rate and a $297 million market capitalization that discounts essentially zero terminal value from the 22-country franchise the company and its partners are now operating. The single load-bearing risk is that the U.S. branded business, which is still 76% of quarterly product revenue at $32.2 million, continues to lose share to authorized generics even as international volume builds, which would keep the company in a net-loss position despite the cost reset. The falsifiable clock is the Q3 2026 print in early November 2026, which is the first quarter in which European year-over-year comparisons stop being distorted by the Recordati transition, and the first quarter in which the company will report any progress on the strategic-alternatives review being run by Barclays.